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Dear Editor,
Vascular lesions of the digestive tract are among the most
frequent causes of gastrointestinal bleeding and iron-
deficiency anemia. We write concerning a particular entity—
gastric antral vascular ectasia (GAVE)—which is endoscopi-
cally characterized by parallel red stripes, angiomatous lesions
at the antral mucosal folds, frequently referred to as watermel-
on stomach. Besides this typical location, it may rarely be
found in the cardia, duodenum, jejunum, and rectum. The
pathogenesis of this entity is still obscure. However, it is as-
sociated with certain comorbidities, such as autoimmune dis-
ease, liver cirrhosis, or chronic renal failure [1, 2].
In patients with active hemorrhage or anemia due to chron-
ic bleeding from GAVE, the available evidence favors endo-
scopic therapy with argon plasma coagulation (APC) or
Nd:YAG. Several medical strategies to reduce GI bleeding
have been described, namely hormonal therapy, octreotide,
tranexamic acid, thalidomide, or prednisolone, none of them
showing ideal outcomes due to severe side effects or
conflicting/scarce results [1, 3–6].
We report the case of a 49-year-old male undergoing dial-
ysis due to membranoproliferative glomerulonephritis. For the
previous 2 years, the patient reported frequent episodes of
melena and anemia, with recurrent need for blood transfusion.
He was diagnosed with gastric antral vascular angiectasia
(GAVE) and submitted to three gastric argon plasma treat-
ments and a trial of thalidomide, which was withdrawn due
to a pulmonary embolism.
He presented to our emergency department with com-
plaints of fatigue and melena for the previous 2 weeks.
Laboratory data revealed low hemoglobin value (6.3 g/dL)
with low median corpuscular volume (65 fL). The patient
was submitted to upper endoscopy, showing multiple gastric
angiodysplasias arranged in radiating streaks (Fig. 1) with
active bleeding, and argon plasma coagulation was performed.
Nevertheless, during hospital stay (1 month), he continued to
require frequent transfusion (10 U of packed red blood cells/
month) despite undergoing three other therapeutic endos-
copies. Further workup, namely a capsule endoscopy, re-
vealed countless angiectasias in the jejunum, with active
hemorrhage.
Facing this severe and refractory gastrointestinal bleeding,
in which endoscopic therapy was insufficient, whether due to
the limited depth of coagulation of APC or the extensive in-
volvement of the small bowel not usually seen in GAVE pa-
tients, therapy with bevacizumab was proposed. Although
there were no published cases with this drug in GAVE, our
experience and the available evidence of this drug in patients
with hereditary-hemorrhagic-telangiectasia (HHT) were sup-
portive and this patient needed an early clinical effect, which
is usually obtained from this drug. Based on the pre-existing
data and the elimination half-life—18 to 20 days—we started
the regimen commonly used in HHT, 5 mg/kg every 3 weeks.
Previously published data also demonstrated similar pharma-
cokinetic parameters between hemodialyzed and normal renal
function patients [7, 8].
After the first administration, a single transfusion was nec-
essary 2 weeks later, and since then a gradual rise in the he-
moglobin values was reported (Graphic 1) as well as normal-
ization of serum iron (ferritin 97 ng/mL; transferrin saturation
of 22%). Parallel improvement in general status and tolerance
for daily activities was stated and after 1 year of therapy the
patient remains free from blood replacement therapy, without
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further episodes of melena or hospital admissions for this con-
dition; in addition, there were no adverse events to report.
Although the etiology of GAVE is unclear, the results ob-
served with bevacizumab suggest a role for VEGF, similarly
to what occurs in other vascular abnormalities; however, fur-
ther studies are required. Most of the treatment strategies cur-
rently considered in GAVE are extrapolations of those being
used in other gastrointestinal vascular diseases. While
bevacizumab has been proved to be effective in other diseases,
as Rendu-Osler-Weber, its use in GAVE has not been ex-
plored, being yet to define the optimum dose/interval, as well
as the duration of the treatment after remission.
In refractory cases, with extensive bowel involvement,
bevacizumab may be considered, having showed in this
patient an almost immediate, significant, and sustained
response.
Fig. 1 Upper digestive
endoscopy revealing
angiodysplasias arranged in


























Graphic 1 Hemoglobin levels
before and after bevacizumab
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